• ALL
  • press releases
  • industry news
press RELEASES

October, 16, 2018

FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for the prevention of pregnancy for up to five years.

read more
press RELEASES

August 27, 2018

Afaxys President, Ronda Dean, appointed to Coastal Community Foundation Board

Coastal Community Foundation (CCF) is pleased to welcome three new members to its Board of Directors.

read more
press RELEASES

September 6, 2018

Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs).

read more
industry NEWS

May 18, 2018

Afaxys Celebrates 10 Years of Serving the Public Health Community

The mission-driven company was founded in 2008 to serve the unique needs of public health providers and their patients. This summer, Charleston-based public health company Afaxys, Inc. celebrates its 10th anniversary.

read more
industry NEWS

April 7, 2016

Johns Hopkins University Public Health Conference Hosts Afaxys CEO Ronda Dean, Special Guest Surgeon General Dr. Vivek Murthy

Afaxys CEO Ronda Dean joined public health industry leaders to speak with Johns Hopkins University students and faculty regarding U.S. and global public health topics, including reliable access to contraception.

read more
industry NEWS

May 11, 2015

Afaxys CEO Ronda Dean Is Empowering Girls During Teen Pregnancy Prevention Month and All Year Long

One changemaker who is making a difference is Ronda Dean, president and CEO of Afaxys Pharma, which is focused on ensuring all women have access to safe, quality and affordable contraceptive products.

read more
industry NEWS

Mar 12, 2015

Mail-Order Birth Control for a Good Cause

Sweet! You can order the pill or EC online and help another woman get birth control at the same time.

read more
press releases

Mar 11, 2015

Afaxys Pharma Announces Launch of EContra™ EZ, Its First Over-the-Counter Emergency Contraceptive

Afaxys Pharma, a division of Afaxys, Inc., today announced the nationwide launch of EContra™ EZ (Levonorgestrel 1.5 mg), Afaxys' first over-the-counter emergency contraceptive offered to the public health sector.

read more
industry NEWS

Feb 12, 2015

Afaxys Pharma Brings the Buy-One-Give-One Model to Birth Control

Afaxys Pharma – a division of Afaxys, Inc., led by president and CEO Ronda Dean – announced a partnership Thursday afternoon with Project Ruby, an online platform that makes low-cost birth control available to women in the U.S.

read more
press releases

Feb 12, 2015

Afaxys Pharma Announces Partnership with Project Ruby (PRJKT RUBY), an Online Platform, to Bring Affordable Contraceptives to Women Worldwide

A U.S. initiative dedicated to empowering women in Africa, Asia, Latin America and the Caribbean to choose and access their preferred contraceptive method.

read more
press releases

Jan 12, 2015

Afaxys Announces Nationwide Availability of Tarina Fe 1/20 to the Public Health Sector, Colleges & Universities

AB-rated equivalent to Loestrin® Fe 1/20 tablets joins Afaxys' oral contraceptive products as company expands product portfolio.

read more
press releases

Nov 13, 2014

Afaxys Announces Wider National Availability of ella® Emergency Contraceptive

ella is available to patients by prescription through their medical and other public health providers or some pharmacists.

read more